Evidence map›Paper›PMID 31517107›Full record

ArticleHeliyon2019

Opsonic monoclonal antibodies enhance phagocytic killing activity and clearance of

Clara J Sei, Bong-Akee Shey, Richard F Schuman, Nimisha Rikhi, Kevin Muema, John D Rodriguez, Luke T Daum, P Bernard Fourie, Gerald W Fischer

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Journal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Clara J SeiLonghorn Vaccines and Diagnostics, Gaithersburg, MD, 20878, USA.
Bong-Akee SheyDepartment of Medical Microbiology, University of Pretoria, Prinshof, Pretoria, South Africa.
Richard F SchumanAntibody and Immunoassay Consultants, Rockville, MD, 20850, USA.
Nimisha RikhiLonghorn Vaccines and Diagnostics, Gaithersburg, MD, 20878, USA.
Kevin MuemaLonghorn Vaccines and Diagnostics, Gaithersburg, MD, 20878, USA.
John D RodriguezLonghorn Vaccines and Diagnostics, San Antonio, TX, 78209, USA.
Luke T DaumLonghorn Vaccines and Diagnostics, San Antonio, TX, 78209, USA.
P Bernard FourieDepartment of Medical Microbiology, University of Pretoria, Prinshof, Pretoria, South Africa.
Gerald W FischerLonghorn Vaccines and Diagnostics, Gaithersburg, MD, 20878, USA.
Emergent BioSolutions (United States) · USUniversity of Pretoria · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with impaired immunity often have rapid progression of tuberculosis (TB) which can lead to highly lethal

methodsBALB/c mice were immunized with ethanol-killed MTB (EK-MTB) and MABs were produced and screened by ELISA for binding to killed and live

resultsTwo MABs (GG9 and JG7) bound to killed and live SMEG and MTB (susceptible and resistant), and promoted OPKA with live MTB. MAB JG7 significantly enhanced OPKA of MTB. Both MABs significantly enhanced clearance of killed MTB from murine blood at 4 and 24 h as measured by qPCR. These opsonic MABs bound to PGN, a major cell wall constituent.

conclusionsAnti-MTB MABs that promote bactericidal phagocytic activity of MTB and enhance clearance of killed MTB from the blood, may offer an immunotherapeutic approach for treatment of MTB bacteremia or sepsis, and augment treatment of multi-drug resistant (MDR) or extensively drug resistant (XDR) TB.

Indexed as

BiotechnologyImmunologyMAB binding activityMicrobiologyMolecular biologyMonoclonal antibodiesMTB clearanceMycobacterium tuberculosisOpsonophagocytosisqPCRSystems biology

Identifiers

PMID31517107
PMCPMC6734336
OpenAlexW2971807743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.